Campbell’s posts lower adjusted profit, while Eli Lilly’s obesity drug trial data draws investor attention

U.S. markets tracked two very different stories on Monday, June 8, 2026. A Yahoo Finance “Stock Movers” segment highlighted that The Campbell’s Company (CPB) was edging higher ahead of the open after reporting third-quarter results. The same segment pointed to Eli Lilly (LLY) as a focus name as investors digested fresh obesity-related trial results from Lilly’s retatrutide program.

Campbell’s reported fiscal third-quarter results for the period ended May 3, 2026. Net sales fell 4% to $2.4 billion. On an adjusted basis, the company reported earnings per share of $0.50, down 32% from $0.73 in the prior-year quarter. Campbell also reported adjusted EBIT of $274 million, down 24% year over year. The company said it reaffirmed its full-year fiscal 2026 guidance.

In a statement accompanying the release, Campbell’s chief executive Mick Beekhuizen said the quarter was generally in line with expectations but remained under pressure, citing top-line softness and inflation-driven margin headwinds. He also said the company was encouraged by early progress in several priority areas, including at-home cooking trends benefitting brands such as Campbell’s, Rao’s, and Swanson in Meals & Beverages, and early signs of progress in Snacks through actions to strengthen its salty snacks portfolio and focus Goldfish on households with kids.

For Lilly, the catalyst came from a June 6 release detailing additional positive results from pivotal Phase 3 trials of retatrutide, which Lilly described as an investigational, first-in-class triple hormone receptor agonist targeting GIP, GLP-1, and glucagon pathways. The company said results from TRIUMPH-1 and TRANSCEND-T2D-1 were presented at the American Diabetes Association’s 86th Scientific Sessions and that TRANSCEND-T2D-1 results were simultaneously published in The Lancet.

In TRIUMPH-1, Lilly reported that participants treated with 12 mg of retatrutide lost an average of 70.3 pounds, or 28.3%, over 80 weeks. It said participants treated with 9 mg lost an average of 64.4 pounds, or 25.9%, over the same period, while the 4 mg arm lost an average of 47.2 pounds, or 19.0%. Lilly added that 65.3% of participants in the 12 mg group achieved a body mass index below 30, and 33.3% reached a BMI below 25, which the company described as healthy BMI.

Lilly also reported longer-term weight outcomes in a pre-specified extension for participants with baseline BMI of 35 and above. In that extension, people continuing on 12 mg through 104 weeks lost an average of 85.0 pounds, or 30.3%. Beyond weight, Lilly said retatrutide reduced knee osteoarthritis pain and improved moderate-to-severe obstructive sleep apnea severity in the trial, including pain reductions up to 4.3 points and a reduction of up to 36.1 events per hour on apnea measurements. In TRANSCEND-T2D-1, Lilly said retatrutide met primary and key secondary endpoints at 40 weeks, including A1C reductions up to 2.0% from a baseline of 7.9%.

Market watchers typically treat obesity-drug efficacy updates as a proxy for a company’s positioning in a crowded GLP-1 and broader incretin market, particularly because durability of weight loss and improvements across obesity-related conditions can affect both uptake and payer discussions. Lilly framed retatrutide’s results as spanning the cardiometabolic spectrum, while Campbell’s narrative remained centered on margin headwinds, operational focus, and maintaining guidance.

Still, important details remain outside what was disclosed in the segment described by Yahoo Finance. The video context did not specify how much CPB or LLY moved on the day, and neither company’s press releases are designed to resolve forward-looking questions such as pricing, long-term tolerability, or ultimate regulatory timing for retatrutide. What to watch next is whether Lilly’s forthcoming submissions and additional trial readouts clarify the program’s benefit-risk profile versus existing obesity therapies, and whether Campbell’s cost actions can offset sales pressure as the fiscal year progresses.